Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: May 16, 2007
Last updated: September 18, 2014
Last verified: November 2011

This phase II trial is studying how well cediranib maleate works in treating patients with relapsed, refractory, or untreated acute myeloid leukemia or high-risk myelodysplastic syndrome. Cediranib maleate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

Condition Intervention Phase
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
de Novo Myelodysplastic Syndromes
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Secondary Myelodysplastic Syndromes
Untreated Adult Acute Myeloid Leukemia
Drug: cediranib maleate
Other: laboratory biomarker analysis
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of AZD2171 in the Treatment of Patients With Acute Leukemia and Myelodysplastic Syndrome.

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • The Number of Confirmed Disease Response: Complete Response (CR), Partial Response (PR), and Hematologic Improvement (HI). A Confirmed Response is Defined to be an Objective Status of CR, PR, or HI Noted on 2 Consecutive Evaluations. [ Time Frame: At the end of cycles 1 and 3 and every 3 cycles thereafter up to 26 cycles ] [ Designated as safety issue: No ]

    Complete Response (CR) requires a repeat bone marrow with < 5% myeloblasts, hemoglobin ≥ 11 g/dl, neutrophils ≥ 1000/mm3, platelets ≥ 100,000/mm3, and no circulating blasts.

    Partial Response (PR) requires a bone marrow blast reduction of 50% or more, hemoglobin ≥ 11 g/dl, neutrophils ≥ 1000/mm3, platelets ≥ 100,000/mm3, and no circulating blasts.

    Hematologic Improvement (HI) requires one of the following:

    1. RBC transfusion independent participants are required to have >1.5 g/dL increase in hemoglobin,
    2. RBC transfusion-dependent participants are required to be transfusion independent,
    3. A 100% increase, and an absolute increase over 500mm^3 in Absolute Neutrophil Count,
    4. Participants with a pretreatment platelet count over 20,000/mm3 require an absolute increase of 30,000/mm^3 or more,
    5. Participants with platelet count below 20,000/mm3 require an increase over 20,000/mm^3 and by at least 100%.

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: Every cycle during treatment and every 6 months for up to 2 years after completion of study treatment ] [ Designated as safety issue: No ]
    Defined as the time from date of registration to date of death due to any cause or date last known alive. The distribution of survival time will be estimated using the method of Kaplan-Meier.

  • Progression-free Survival [ Time Frame: Every 3 courses during treatment and then at 3 months and every 6 months for up to 2 years after completion of study treatment ] [ Designated as safety issue: No ]

    Defined as the time from date of registration to date that disease progression was documented, death, or last date that progression-free status was documented, whichever comes first. Estimated using the method of Kaplan-Meier.

    Disease progression is defined as one of the following:

    • A ≥ 50% increase in bone marrow blasts from the best response, or
    • A 50% or greater decrement from maximum remission/response levels in neutrophils or platelets, or
    • A reduction in hemoglobin concentration by at least 1.5 g/dl, or
    • Transfusion dependence (without alternative explanation and sustained for at least 2 weeks).

  • Duration of Response [ Time Frame: Every 3 courses up to 26 courses ] [ Designated as safety issue: No ]
    Measured from the time criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Estimated using the method of Kaplan-Meier.

  • The Number of Patients That Report Adverse Events Possibly, Probably, or Definitely Related to AZD2171. [ Time Frame: Continuously during treatment up to 26 courses ] [ Designated as safety issue: Yes ]
    Graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. All adverse events determined to be possibly, probably, or definately related to AZD2171 are included in this analysis.

Enrollment: 39
Study Start Date: May 2008
Study Completion Date: March 2012
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (enzyme inhibitor therapy)
Patients receive oral cediranib maleate QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
Drug: cediranib maleate
Given orally
Other Names:
  • AZD2171
  • Recentin
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:


I. Evaluate the objective response rate in patients with relapsed, refractory, or untreated acute myeloid leukemia or high-risk myelodysplastic syndromes treated with AZD2171 (cediranib maleate).


I. Determine the toxicity of this drug in these patients. II. Determine the response duration, event-free survival, and overall survival of patients treated with this drug.

III. Determine the hematological response rate in patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to disease (acute myeloid leukemia vs myelodysplastic syndromes).

Patients receive oral cediranib maleate once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy at baseline and on day 28 for correlative studies. Samples are analyzed for circulating endothelial cells, VEGF receptor expression, and leukemic blasts via flow cytometry and microvessel density via histopathological techniques.

After completion of study treatment, patients are followed up at 3 months and then every 6 months for up to 2 years.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed acute myeloid leukemia (AML) ormyelodysplastic syndromes meeting 1 of the following criteria:

    • Relapsed AML meeting any of the following criteria:

      • Good-risk cytogenetics (inv[16], t[8;21], or t[15;17]) in second orgreater relapse

        • Patients with AML t(15;17) must have failed prior tretinoin and arsenic-containing regimens AND progressed orrelapsed within 12 months of therapy
      • In first or greater relapse
    • Resistant AML

      • Unable to achieve first complete remission after at least 2 inductionregimens
    • Untreated AML meeting any of the following criteria:

      • At least 60 years of age
      • Preceding MDS
    • MDS

      • International Prognosis Scoring System (IPSS) risk groupof intermediate-2 or higher
  • Patients with relapsed disease after allogeneic hematopoietic stem cell transplantation (HSCT) must be off allimmunosuppressive medications for at least 30 days and have no symptoms orsigns of graft-vs-host disease
  • No active CNS metastasis

    • Patients with clinical signs of CNS disease or a history of CNS diseasewithin the past 6 months are required to undergo lumbar puncture to excludeCNS involvement
  • No symptomatic leukostasis or requirement for leukapheresis
  • Not eligible for allogeneic HSCTAND no suitable donor at the time of study entry

    • Patients who areeligible for HSCT, informed of the option, and choose not to proceed to HSCTare allowed
  • ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
  • Bilirubin normal
  • AST and/or ALT ≤ 2.5 times upper limit of normal
  • Creatinine normal OR creatinine clearance ≥ 60 mL/min
  • No proteinuria ≥ 1+ on 2 consecutive urinalysis taken ≥ 1 week apart
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No HIV positivity
  • LVEF ≥ 45% by echocardiography
  • Mean QTc ≤ 500 msec (with Bazett's correction)
  • No other significant ECG abnormality
  • No history of familial long QT syndrome
  • No disseminated intravascular coagulation
  • No history of allergic reactions attributed to compounds of similar chemical orbiological composition to AZD2171
  • No concurrent uncontrolled illness, including, but not limited to, any of the following:

    • Hypertension
    • Thyroid disease
    • Ongoing or active infection
    • Symptomatic congestive heartfailure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • NYHA class III-IV heart disease

      • NYHA class II heart disease controlled with treatment allowed
    • Psychiatric illness or social situations that would limit study compliance
  • See Disease Characteristics
  • More than 4 weeks since prior chemotherapy (6 weeks fornitrosoureas or mitomycin C), radiotherapy, or major surgery and recovered

    • Hydroxyurea allowed to control peripheral blast count> 20,000/mcL prior to study entry and during the first 3 days of study therapy
  • More than 4 weeks since prior and no concurrent growth factor or other cytokine support
  • At least 30 days since prior investigational agents or participation in aninvestigational trial
  • No more than 3 prior courses of induction chemotherapy

    • Induction chemotherapyis defined as that intended to induce complete remission and given at a time thatthe patient has active disease
  • No concurrent CYP interactive medications
  • No other concurrent investigational agents
  • No concurrent drugs or biologics with proarrhythmic potential
  • Prior and concurrent hydroxyurea allowed to control peripheral blast count> 20,000/mcL during the first 3 days of study therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00475150

United States, District of Columbia
Howard University Hospital
Washington, District of Columbia, United States, 20060
United States, Florida
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980
United States, Maryland
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States, 21287
United States, Michigan
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Principal Investigator: Mark Juckett Mayo Clinic
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00475150     History of Changes
Obsolete Identifiers: NCT01646983, NCT01664455
Other Study ID Numbers: NCI-2009-00129, NCI-2009-00129, CDR0000544833, MCCRC-MC048H, MC048H, 7135, N01CM62205, P30CA015083
Study First Received: May 16, 2007
Results First Received: March 22, 2013
Last Updated: September 18, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Neoplasm Metastasis
Bone Marrow Diseases
Hematologic Diseases
Neoplasms by Histologic Type
Neoplastic Processes
Pathologic Processes
Precancerous Conditions
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses processed this record on February 27, 2015